跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MET-X
首页
药物
MET-X
MET-X
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Small peptides and methods for treatment of inflammation
US 8012934 B2
申请人: MOWYCAL LENDING LLC
优先权: 2002
US
19 件公开
Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US 7601716 B2
申请人: CEPHALON INC
优先权: 2007
US
6 件公开
Derivatives of magainin and methods of production thereof
US 7232800 B2
申请人: SHANGHAI HUAYI BIOTECH LAB
优先权: 2001
CN
US
5 件公开
CONSENSUS PEPTIDES IN HYA FOR USE IN TREATING DEGENERATED JOINTS
EP 4487863 A1
申请人: NUPEP AS
优先权: 2023
EP
WO
5 件公开
6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors
US 8546393 B2
申请人: ALBERT EVA
优先权: 2007
US
5 件公开
Acyclovir-peptide analogs
US 7553812 B2
申请人: UNIV MISSOURI
优先权: 2004
US
4 件公开
Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
US 2006135438 A1
申请人: MITRA ASHIM K
优先权: 2005
US
4 件公开
Quinoline compound composing 1,2,4-triazine-dione and use thereof
US 8822465 B2
申请人: XU HUA
优先权: 2012
US
4 件公开
CONSENSUS PEPTIDES IN HYA
EP 4739277 A1
申请人: NUPEP AS
优先权: 2023
CN
EP
WO
3 件公开
EP 4487834 A1
申请人: NUPEP AS
优先权: 2023
EP
PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR DIABETES OR OBESITY
US 2011046046 A1
申请人: HARA HIROSHI
优先权: 2008
CN
US
2 件公开
第 1 / 10 页
上一页
下一页
药物
反馈